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Background: Previous studies have suggested links between chronic obstructive pulmonary 
disease (COPD), cardiovascular disease, and abdominal obesity. Although abdominal   visceral 
fat is thought to be associated with cardiovascular risk factors, the degree of visceral fat 
  accumulation in patients with COPD has not been directly studied. The aim of this study was 
to investigate the abdominal visceral fat accumulation and the association between visceral fat 
and the severity and changes in emphysema in COPD patients.
Methods: We performed clinical and laboratory tests, including pulmonary function, dyspnea 
score, and the six-minute walking test in COPD patients (n = 101) and control, which included 
subjects with a smoking history but without airflow obstruction (n = 62). We used computed 
tomography to evaluate the abdominal visceral fat area (VFA), subcutaneous fat area (SFA), 
and the extent of emphysema.
Results: The COPD group had a larger VFA than the control group. The prevalence of non-obese 
subjects with an increased VFA was greater in the Global Initiative for Chronic Obstructive 
Lung Disease Stages III and IV than in the other stages of COPD. The extent of emphysema was 
inversely correlated with waist circumference and SFA. However, VFA did not decrease with the 
severity of emphysema. VFA was positively correlated with the degree of dyspnea.
Conclusion: COPD patients have excessive visceral fat, which is retained in patients with more 
advanced stages of COPD or severe emphysema despite the absence of obesity.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease with systemic comorbid 
conditions including hypertension, diabetes mellitus, and cardiovascular diseases due 
to systemic inflammation.1–3 Cardiovascular disease, which is often related to obesity, 
accounts for approximately 30% of mortality in more advanced COPD patients who 
tend to have muscle loss.4,5 Although the underlying mechanisms are presently unclear, 
chronic systemic inflammation is considered to increase susceptibility to cardiovascular 
disease in COPD patients.6
Several studies have showed that COPD patients have one or more components 
of metabolic syndrome, and that coexisting metabolic syndrome is associated with 
  systemic inflammation and physical inactivity.7,8 Abdominal obesity, particularly 
visceral adiposity, is a key feature of metabolic syndrome and is associated with 
cardiovascular risk factors.9 This is because the accumulation of visceral fat causes 
endocrine disturbances such as adipokine dysregulation.10 Features of acute-phase 
activation and low-grade inflammation, including elevated levels of fibrinogen, International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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C-reactive protein, and interleukin (IL)-6, are particularly 
associated with central or visceral obesity.11 Adiponectin 
is an anti-inflammatory cytokine that is believed to control 
cardiovascular diseases. High levels of IL-6 or tumor necrosis 
factor-α and low levels of adiponectin are observed when 
there is an excess accumulation of visceral fat.11
In general, physical inactivity is one of the most   important 
determinants of the accumulation of visceral fat,12 which 
is commonly observed in COPD patients.13 Although 
this   information suggests an association between visceral 
adiposity and COPD, visceral fat accumulation in COPD 
patients has not been directly investigated.
Abdominal obesity is generally assessed by anthropometric 
measurements such as waist circumference and waist-to-hip 
ratio to estimate the amount of abdominal adipose tissue; 
however, it has been reported that the association between 
cardiovascular risk factors and visceral fat measured directly 
with computed tomography (CT) is stronger than the 
associations between these factors and such anthropometric 
measurements.9,14
We hypothesized that COPD patients have excessive 
  visceral fat and that its accumulation has systemic 
  consequences such as cardiovascular disease. Furthermore, 
visceral fat accumulation is probably retained in patients with 
more advanced stages of COPD and with severe emphysema, 
and this might continuously induce systemic comorbidities. 
To examine our hypotheses, we compared visceral fat 
accumulation in COPD and control groups by using CT. 
With regard to the COPD group, we also investigated the 
relationship between visceral fat accumulation and the extent 
of emphysema, as well as the severity of COPD.
Methods
subjects
For the present cross-sectional study, we enrolled 163 
  consecutive Japanese men who visited the Respiratory Care 
Clinic, Nippon Medical School, Tokyo, Japan, from January 
to December 2007. The inclusion criteria were as follows: 
(1) exertional dyspnea, prolonged cough, or expectoration 
compatible with clinical symptoms of COPD, as described in 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines15 and (2) current or previous smoker 
(number of pack-years $20). We excluded those who had 
(1) a history of atopy or any apparent clinical features of 
asthma, (2) received any systemic corticosteroid regimen in 
the preceding 3 months, (3) experienced exacerbation during 
the preceding 3 months, or (4) had other respiratory diseases 
such as bronchiectasis or pulmonary fibrosis.
We divided the subjects into a COPD group and a 
control group according to the results of pulmonary 
function tests; the COPD group included those who had 
a ratio of forced expiratory volume in 1 second (FEV1) to 
forced vital capacity (FVC) of ,0.7 after bronchodilator 
administration.15
The present study was approved by the Ethics Committee 
of Nippon Medical School, and all patients were enrolled 
after they had provided appropriate informed consent.
Pulmonary function testing
Pulmonary  functional  parameters,  including  post- 
bronchodilator FEV1, carbon monoxide diffusing   capacity, 
vital capacity, and FVC, were measured according to 
the American Thoracic Society (ATS) guidelines16 by 
using   computer-coupled equipment for lung function 
testing (Chestac; Chest Co., Tokyo, Japan). Reference 
  post-  bronchodilator values were based on standards of the 
  Japanese Respiratory Society.17 COPD severity was classified 
as Stage I, II, III, or IV , depending on the FEV1% predicted, 
as described in the GOLD guidelines.15
Arterial blood gases
Arterial blood was drawn from a radial artery while the 
subjects were breathing room air in a seated position. Arterial 
partial pressures of oxygen and carbon dioxide (PaO2 and 
PaCO2, respectively) were analyzed with a blood gas analyzer 
(Stat Profile® pHOx® Plus; Nova Biomedical, MA).
Modified Medical Respiratory Council 
dyspnea scale
The degree of dyspnea was assessed using the Modified 
Medical Respiratory Council (MMRC) dyspnea scale.18
exercise capacity
The 6-minute walk test (6MWT) was performed according 
to ATS standards,19 during which oximetry was performed at 
10-second intervals with a pulse oximeter (PULSOX; Teijin 
Pharma Ltd, Tokyo, Japan).
Anthropometry
Body height and weight were measured (BWB-800 
and Rainbow scale, respectively; Tanita Co, Tokyo, 
Japan). Body mass index (BMI) was calculated as the 
ratio of body weight to height (m2). The criteria for BMI 
classification of the Japan Society for the Study of   Obesity 
were applied as follows: BMI , 18.5 kg/m2, under-
weight; 18.5 kg/m2 # BMI , 25 kg/m2, normal weight; International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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25 kg/m2 # BMI , 30 kg/m2, obese; and BMI $ 30 kg/m2, 
severely obese.20 Waist circumference at the umbilicus 
level was measured during the late exhalation phase while 
  standing. Fat-free mass (FFM) and fat mass (FM) were 
measured by bioelectrical impedance analysis at frequencies 
of 5, 50, 250, and 500 kHz (InBody 3.2; Biospace Co Ltd, 
Seoul, Republic of Korea). The FFM index (FFMI) and FM 
index (FMI) were calculated as the ratio of FFM or FM to 
height (m2), respectively.
Comorbidities
The degree of comorbidity was determined using the 
Charlson index,21 which has been shown to be associated with 
mortality in COPD patients.22 Higher scores in the Charlson 
index indicate more coexisting conditions.
Analysis of emphysema  
by computed tomography
The percentage of low-attenuation area (LAA%) in high-
resolution CT (HRCT) images was calculated as described 
previously.23 HRCT was performed using a LightSpeed Pro16 
CT scanner (General Electric Co, Tokyo, Japan) with the 
following settings: 1.25-mm collimation, 0.8-second scan 
time (rotation time), 120 kV , and 100–600 mA. The cut-off 
level between normal lung density and the LAA was defined 
as −940 HU.
Analysis of the visceral fat area  
and subcutaneous fat area  
by computed tomography
The visceral fat area (VFA) and subcutaneous fat area (SFA) 
were assessed using cross-sectional CT scans at the umbilicus 
level as described previously.24 The VFA cut-off value for 
visceral adiposity in Japanese men according to the Japan 
Society for the Study of Obesity is 100 cm2.20
Parameters related to metabolic 
syndrome
Waist circumference was measured as described above. 
Systolic and diastolic blood pressures were measured in 
the right arm, employing the conventional cuff method 
using an automated sphygmomanometer (BP-203RV 
IIIB; Omron-Colin Co Ltd, Tokyo, Japan). Blood samples 
were collected from an antecubital vein after overnight 
fasting; serum triglyceride, high-density lipoprotein 
(HDL)-cholesterol, and fasting blood glucose levels were 
measured.
statistical analysis
Differences in quantitative variables between the control 
and COPD groups were assessed for significance by using 
the unpaired Student’s t-test or the Mann–Whitney U-test, 
where appropriate. Qualitative data were analyzed using the 
  chi-square test. The Kruskal–Wallis test and one-way   analysis 
of variance (ANOVA), with the Tukey–Kramer procedure 
for post-hoc multivariate comparisons of means, were used 
to compare non-parametric and parametric data, respectively, 
among GOLD stages. The Pearson correlation coefficient 
or the Spearman rank correlation coefficient was used to 
evaluate relationships between LAA% and VFA, SFA, BMI, 
waist circumference, FMI, and FFMI, where appropriate. 
All statistical tests were 2-tailed, and P values ,0.05 were 
  considered significant. Data were analyzed using SPSS 
(v 11.0.1 for Windows; SPSS Inc, Chicago, IL).
Results
subject characteristics
The COPD group (n = 101) had a higher smoking index 
than the control group (n = 62) (Table 1). No significant 
differences in BMI or waist circumference were observed 
between the two groups.
Table 1 subject characteristics
Control COPD P value
subjects (n) 62 101 –
Age (years) 68.5 (60.0–75.0) 69.0 (64.0–75.0) 0.126
smoking index  
(pack-years)
50.0 (30.0–69.4) 70.0 (40.5–102.5) 0.004
FeV1 (L) 2.7 ± 0.7 1.7 ± 0.6 ,0.0001
FeV1/FVC (%) 77.5 (74.1–83.0) 50.7 (42.3–59.2) ,0.0001
FeV1% predicted (%) 89.9 ± 15.7 58.6 ± 19.3 ,0.0001
DLCO/VA 3.6 ± 1.1 2.7 ± 0.9 ,0.0001
PaO2 (mmhg) 88.5 ± 7.5 80.6 ± 10.5 ,0.0001
PaCO2 (mmhg) 41.5 ± 4.2 40.2 ± 3.9 0.067
LAA% (%) 18.8 ± 11.6 33.6 ± 13.2 ,0.0001
BMI (kg/m2) 23.0 ± 3.4 23.4 ± 3.2 0.451
Waist  
circumference (cm)
84.8 ± 9.6 87.6 ± 8.9 0.070
FMI (kg/m2) 5.3 ± 1.9 5.9 ± 2.0 0.037
FFMI (kg/m2) 17.7 ± 1.9 17.5 ± 1.7 0.382
MMrC 0.65 ± 0.8 1.16 ± 1.0 0.001
6MWD (m) 525.8 ± 79.8 460.3 ± 105.0 ,0.0001
Charlson index 2.5 ± 1.0 2.8 ± 0.9 0.100
Note: Data are presented as the mean ± standard deviation, median (interquartile 
range), or numbers.
Abbreviations:  6MWD,  six-minute  walk  test  distance;  BMI,  body  mass  index; 
COPD, chronic obstructive pulmonary disease; DLCO, carbon monoxide diffusion 
capacity; FeV1, forced expiratory volume in 1 second; FFMI, fat-free mass index; 
FMI, fat mass index; FVC, forced vital capacity; gOLD, global Initiative for Chronic 
Obstructive  Lung  Disease;  LAA%,  percentage  of  low-attenuation  area;  MMrC, 
modified Medical Research Council; PaO2, partial pressure of oxygen; PaCO2, partial 
pressure of carbon dioxide; VA, alveolar volume.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Regarding metabolic parameters, the COPD group had 
significantly higher systolic blood pressure and lower fasting 
glucose levels than the control group. No significant differ-
ences were observed between the two groups with respect to 
diastolic blood pressure, triglycerides, or HDL-cholesterol 
levels. Significantly more subjects in the COPD group 
were receiving treatment for hypertension or dyslipidemia 
(Table 2).
Visceral fat area
The VFA was significantly greater in the COPD group than 
in the control group (P = 0.023) (Figure 1). The prevalence 
of patients with VFA $ 100 cm2 (the cut-off value for 
abdominal obesity) in the COPD and control groups was 
52.5% and 38.7%, respectively. No difference in SFA was 
observed between the two groups (data not shown).
Muscle depletion and visceral  
fat accumulation
Data on body composition and abdominal fat areas at various 
COPD stages are shown in Table 3. Stages III and IV were 
combined into one group designated “Stages III+IV”, because 
the number of subjects in Stage IV was so small that these 
subjects could not be examined separately.
The FFMI in Stages III+IV was significantly lower than 
that in both Stage II (P = 0.046) and Stage I (P = 0.060). 
This suggests that FFMI decreases with the progression of 
COPD. In contrast, VFA tended to increase with COPD 
progression, although not all differences were statisti-
cally significant. The percentages of non-obese patients 
with VFA $ 100 cm2 in Stages I, II, and III+IV were 
15.8%, 19.0%, and 45.0%, respectively. The prevalence of 
nonobese patients with VFA $ 100 cm2 in Stages III+IV 
was significantly higher than that in the other stages 
(P = 0.013).
Table 2 Comparison of metabolic profiles between the COPD and control groups
Control COPD P value
subjects (n) 62 101 –
systolic blood pressure (mmhg) 129.3 ± 14.9 135.9 ± 18.3 0.033
Diastolic blood pressure (mmhg) 79.7 ± 10.4 81.9 ± 11.7 0.275
Fasting glucose (mg/dL) 102.5 (88.5–116.5) 95.0 (87.0–103.0) 0.005
Triglycerides (mg/dL) 104.0 (62.0–146.0) 112.0 (75.5–148.5) 0.498
hDL-cholesterol (mg/dL) 56.0 (45.0–67.0) 56.5 (44.5–68.5) 0.832
hypertension treatment 17 (27.4) 50 (49.5) 0.005
Diabetes treatment 11 (17.7) 15 (14.9) 0.625
Dyslipidemia treatment 10 (16.1) 44 (43.6) ,0.0001
Note: Data are presented as the mean ± standard deviation, median (interquartile range), or numbers (%).
Abbreviations: COPD, chronic obstructive pulmonary disease; hDL, high-density lipoprotein.
relationships between emphysema  
and waist circumference, subcutaneous 
fat area, and visceral fat area
Although the LAA% was inversely correlated with waist 
circumference (P = 0.002, r = −0.322) and SFA (P , 0.0001, 
r = −0.454) (Figure 2A and B, respectively), it was not cor-
related with VFA (P = 0.194, Rho = −0.125) (Figure 2C). The 
LAA% was also inversely correlated with BMI (P , 0.0001, 
r = −0.507), FMI (P , 0.0001, r = −0.385), and FFMI 
(P , 0.0001, r = –0.491).
Visceral fat area and dyspnea  
and exercise capacity
VFA was positively correlated with the MMRC scale 
score (P = 0.013, Rho = 0.252) but not with the 6MWD, or 
minimum oxygen or the change in oxygen saturation during 
the 6MWT.
Discussion
The primary finding of the present study is that COPD 
patients have excessive visceral fat and its accumulation is 
retained in the more advanced stages of COPD and severe 
emphysema despite the absence of obesity. To the best of 
our knowledge, there has been no previous study of the 
association between COPD and abdominal visceral fat 
accumulation measured directly by CT.
The present study yields several interesting and novel 
findings. First, the COPD group had a larger VFA than the 
control group, although there was no difference in BMI or 
waist circumference between the two groups. Furthermore, 
the median VFA in the COPD group was $100 cm2. This 
is the cut-off value for VFA in Japanese men.20 This finding 
may be related to the significantly higher prevalence of 
subjects receiving treatment for hypertension or dyslipidemia 
in the COPD group than in the control group. A previous International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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investigation by the Japan Society for the Study of Obesity 
also suggests that the risk of having at least one obesity-
related disorder such as dyslipidemia, hypertension, or 
hyperglycemia increases at VFA $ 100 cm2; furthermore, 
the number of obesity-related disorders increases with an 
increase in VFA.20
Second, the prevalence of non-obese patients with exces-
sive visceral fat was highest in Stages III+IV of COPD. 
In addition, patients with COPD and severe emphysema 
retained visceral fat despite the absence of obesity. Such 
patients are often found to be malnourished.25 Indeed, 
decreased skeletal muscle mass was observed in the more 
severe COPD stages. Furthermore, BMI, waist circum-
ference, FFMI, FMI, and SFA decreased with increasing 
emphysematous severity in the present study. Similarly, 
Ogawa et al have reported that BMI and subcutaneous fat 
are lower in predominantly emphysematous COPD patients, 
although thoracic subcutaneous fat was measured rather 
than abdominal fat.26 Previously, we reported that the extent 
of emphysema observed in HRCT is associated with FFM 
and FM loss in COPD in a different cohort from that in the 
present study.27
Taken together, these results indicate that COPD 
patients show simultaneous muscle loss and excess vis-
ceral fat accumulation, particularly in the more severe 
stages of COPD and emphysema. There are several pos-
sible explanations for this observation. It has been reported 
that skeletal muscle mass in advanced stages of COPD 
decreases with increased energy expenditure, physical 
inactivity owing to dyspnea, decreased exercise capacity, 
inadequate diet, and/or systemic inflammation.13,28,29 
Decreased skeletal muscle mass may result in further 
physical inactivity, leading to excess visceral fat accumu-
lation, especially in the more advanced stages of COPD 
and/or severe emphysema.
Last, visceral fat accumulation in COPD increased 
with the severity of dyspnea in the present study. This may 
be related to physical inactivity. Serres et al showed that 
physical inactivity is a consequence of the so-called dyspnea 
spiral,30 in which COPD patients tend to adopt a sedentary 
lifestyle to avoid dyspnea. However, our analysis did not 
show a significant correlation between 6MWD and visceral 
fat accumulation. Although the 6MWD could be indicative 
of exercise capacity, it does not necessarily reflect the total 
amount of physical activity in daily life. Further studies are 
needed to assess this possible association by using physical 
activity monitors or accelerometers.
Our findings may partially explain the increased risk of 
cardiovascular diseases in COPD patients, especially in those 
with more advanced stages. COPD patients, even those with 
a normal BMI, may have an increased risk of cardiovascular 
disease owing to excessive accumulation of visceral fat. 
In this regard, careful assessment of abdominal obesity is 
Table 3 Differences in variables related to muscle and fat between the gOLD stages of COPD
Stage I Stage II Stages III+IV P value
subjects (n) 19 42 40 –
FMI (kg/m2) 5.6 (4.3–6.9) 6.2 (5.1–7.0) 5.8 (4.8–6.6) 0.713
FFMI (kg/m2) 18.0 ± 1.3 17.8 ± 1.9 16.9 ± 1.6 0.022
BMI (kg/m2) 23.7 (22.3–25.4) 24.7 (21.9–26.5) 22.4 (21.1–23.8) 0.463
Waist circumference (cm) 87.4 ± 8.8 87.7 ± 8.4 87.7 ± 9.8 0.990
VFA (cm2) 97.2 ± 43.5 107.2 ± 48.2 125.3 ± 60.5 0.117
sFA (cm2) 107.7 ± 47.2 121.4 ± 49.6 110.0 ± 47.2 0.454
Note: Data are presented as the mean ± standard deviation, median (interquartile range), or numbers.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FFMI, fat-free mass index; FMI, fat mass index; gOLD, global Initiative for Chronic 
Obstructive Lung Disease; sFA, subcutaneous fat area; VFA, visceral fat area.
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needed for non-obese COPD patients, especially those at 
more advanced stages or with severe emphysema, because 
they tend to show abdominal subcutaneous fat loss.
Although it is often hypothesized that systemic 
inflammation in COPD is the result of a “spill-over” of airway 
inflammation into the systemic circulation,31 adipose tissue-
mediated inflammation in COPD has also recently been 
proposed.32 Visceral adiposity is generally associated with 
adipocyte dysfunction, leading to systemic inflammation.33 
In a previous study, adipocyte dysfunction was found to 
be associated with adipose tissue hypoxia.34 Therefore, we 
hypothesize that excessive visceral fat is another source of 
systemic inflammation in COPD and contributes toward 
altered body composition. In particular, patients with reduced 
pulmonary function, who also tend to be hypoxic, may be 
more susceptible to this effect, because systemic hypoxia is 
also associated with systemic inflammation.35
The present study has raised several questions, which 
need to be explored in future studies. We should investigate 
the prognosis or clinical outcomes in COPD patients who 
have normal BMI/waist circumference, increased visceral 
fat, and depleted muscle. We need also to investigate the 
influence of corticosteroids on visceral fat accumulation and 
the effects of pulmonary rehabilitation on COPD patients. 
Abdominal adipose tissue is considered to be a source of 
inflammation as described above,33 and is associated with 
insulin resistance and cardiovascular diseases.9 Moreover, 
FFMI is an even more important determinant of prognosis 
in patients with moderate to severe COPD than BMI.36 
In this regard, we believed that a cohort of COPD patients 
with normal BMI/waist circumference, increased visceral 
fat, and depleted muscle as shown in the present study 
have a bad prognosis characterized by decreased activity 
of daily living and increased exacerbations or mortality. 
However, the role of adipose tissue in the pathogenesis 
of systemic inflammation in COPD has not yet been fully 
examined. In addition, COPD patients are often treated with 
  glucocorticoids for exacerbations or with an inhalation in 
more advanced stages or in daily treatment for asthma.15 
Although no patients in the present study received oral 
corticosteroids in the preceding 3 months of the evaluation, 
it should be noted that systemic corticosteroid therapy may 
induce visceral obesity as a result of glucocorticoid-mediated 
redistribution of stored energy and the stimulatory effect on 
intake.37 When it comes to a possible strategy for disease 
management, pulmonary   rehabilitation is suggested in 
anticipation of not only increased muscle strength but also 
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Figure 2 relationships between the percentage of low-attenuation area (LAA%) 
and waist circumference, visceral fat area (VFA), and subcutaneous fat area (sFA) 
in  patients  with  chronic  obstructive  pulmonary  disease  (COPD).  Significant 
correlations  were  observed  between  the  LAA%  and  (A)  waist  circumference 
(r = −0.322, P = 0.002) and (B) sFA (r = −0.455, P , 0.0001) but not (C) VFA 
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visceral fat loss. Visceral fat loss after aerobic exercise 
training improves glucose metabolism and is associated 
with the reversal of insulin resistance.38 On the basis of 
the findings outlined above, we believe that further   studies 
are needed to reveal the potential influence of visceral 
adiposity on the prognosis of COPD patients with normal 
BMI/waist circumference and the possible implications for 
corticosteroids and pulmonary rehabilitation in COPD.
Our study is subject to certain limitations. First, the VFA 
cut-off value of 100 cm2 was used on the basis of the accepted 
Japanese standard,20 because this is the only available value 
for healthy Japanese subjects. Second, in the present study, 
only Japanese men were enrolled to exclude the influence 
of gender differences in VFA. It is also likely that there are 
ethnic differences with respect to VFA; therefore, inter-ethnic 
differences need to be studied, and a larger sample should 
be used. A recent study has indicated the presence of an 
obesity epidemic in most but not all racial and ethnic groups.39 
This suggests that additional studies involving other ethnic 
groups should be conducted. Last, the effects of excessive 
visceral fat on comorbidities, were not fully evaluated in this 
study. Further prospective studies are needed to investigate 
causal relationships between visceral fat accumulation and 
comorbidities.
In conclusion, COPD patients have excessive visceral fat, 
which is retained in patients with more advanced stages of 
COPD or severe emphysema despite the absence of obesity. 
The status of malnutrition appears to vary among COPD 
stages and phenotypes; therefore, different intervention 
regimens should be developed for COPD subtypes.
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